Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients

Pemphigus is an autoimmune mucocutaneous blistering disease caused by autoantibodies against desmogleins. Rituximab effectively treats pemphigus by inducing remission and rapidly reducing corticosteroid dosage. In Korea, the high cost of rituximab had been a burden until the National Health Insuranc...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ahreum, Jang, Jieun, Lee, Ayeong, Min, Seo Yeon, Lee, Sang Gyun, Kim, Soo-Chan, Shin, Jaeyong, Kim, Jong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379325/
https://www.ncbi.nlm.nih.gov/pubmed/35983042
http://dx.doi.org/10.3389/fimmu.2022.932909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379325/
https://www.ncbi.nlm.nih.gov/pubmed/35983042
http://dx.doi.org/10.3389/fimmu.2022.932909

Ejemplares similares